Bristol-Myers Squibb Co
BRM
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
Markets appear overly bearish on the company despite the company having attracting growth options.
stocks
Market overreacts to earnings miss from moated ASX retailer
Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,221.30 | 18.70 | -0.20% |
| CAC 40 | 7,843.04 | 126.65 | -1.59% |
| DAX 40 | 24,273.12 | 89.97 | -0.37% |
| Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,829.91 | 490.77 | 1.94% |
| NASDAQ | 21,449.29 | 47.24 | -0.22% |
| Nikkei 225 | 42,480.99 | 326.83 | -0.76% |
| NZX 50 Index | 13,093.53 | 14.03 | 0.11% |
| S&P 500 | 6,439.32 | 27.59 | -0.43% |
| S&P/ASX 200 | 8,954.30 | 12.60 | -0.14% |
| SSE Composite Index | 3,883.56 | 57.80 | 1.51% |